Skip to main content

Pancreatic cancer and personalized medicine: Can genomics facilitate early diagnosis or improve therapeutic outcomes?

Publication ,  Journal Article
Strimpakos, AS; Hoimes, C; Syrigos, KN; Saif, MW
Published in: Current Pharmacogenomics and Personalized Medicine
January 1, 2010

Despite recent advances in diagnosis and treatment of certain cancers such as breast, colon and prostate cancers, pancreatic cancer remains a deadly malignancy with a mortality rate almost equal to its incidence. The survival benefit after all possible medical interventions is still disappointing for the majority of patients with pancreatic cancer. Improving the quality of life and increasing survival remain as the key objectives of pharmacogenomics and clinical investigation in pancreatic cancer. There are several notable genetic loci (e.g., RRM1, CDA, DPYD, UGT1A1) known to predict the toxicity of drugs used in pancreatic cancer such as gemcitabine, capecitabine, platinum agents and irinotecan. Other genes are associated with efficacy of these drugs (e.g., HuR, DCK, TS, ERCC1), although prospective validation of their clinical utility is still required. This paper presents the latest research advances in pharmacogenomics of pancreatic cancer with a view to molecular guidance for clinical diagnosis and individualized patient care. © 2010 Bentham Science Publishers Ltd.

Duke Scholars

Published In

Current Pharmacogenomics and Personalized Medicine

DOI

EISSN

1875-6913

ISSN

1875-6921

Publication Date

January 1, 2010

Volume

8

Issue

1

Start / End Page

73 / 88

Related Subject Headings

  • Pharmacology & Pharmacy
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Strimpakos, A. S., Hoimes, C., Syrigos, K. N., & Saif, M. W. (2010). Pancreatic cancer and personalized medicine: Can genomics facilitate early diagnosis or improve therapeutic outcomes? Current Pharmacogenomics and Personalized Medicine, 8(1), 73–88. https://doi.org/10.2174/1875692111008010073
Strimpakos, A. S., C. Hoimes, K. N. Syrigos, and M. W. Saif. “Pancreatic cancer and personalized medicine: Can genomics facilitate early diagnosis or improve therapeutic outcomes?Current Pharmacogenomics and Personalized Medicine 8, no. 1 (January 1, 2010): 73–88. https://doi.org/10.2174/1875692111008010073.
Strimpakos AS, Hoimes C, Syrigos KN, Saif MW. Pancreatic cancer and personalized medicine: Can genomics facilitate early diagnosis or improve therapeutic outcomes? Current Pharmacogenomics and Personalized Medicine. 2010 Jan 1;8(1):73–88.
Strimpakos, A. S., et al. “Pancreatic cancer and personalized medicine: Can genomics facilitate early diagnosis or improve therapeutic outcomes?Current Pharmacogenomics and Personalized Medicine, vol. 8, no. 1, Jan. 2010, pp. 73–88. Scopus, doi:10.2174/1875692111008010073.
Strimpakos AS, Hoimes C, Syrigos KN, Saif MW. Pancreatic cancer and personalized medicine: Can genomics facilitate early diagnosis or improve therapeutic outcomes? Current Pharmacogenomics and Personalized Medicine. 2010 Jan 1;8(1):73–88.

Published In

Current Pharmacogenomics and Personalized Medicine

DOI

EISSN

1875-6913

ISSN

1875-6921

Publication Date

January 1, 2010

Volume

8

Issue

1

Start / End Page

73 / 88

Related Subject Headings

  • Pharmacology & Pharmacy
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences